Maryland Department of Health - Reports on Standing Orders and Opioid Overdose Reversal Drugs

This Maryland bill requires health care providers issuing standing orders for opioid overdose reversal drugs to let patients choose any FDA-approved formulation of the medication. It also mandates that the Maryland Department of Health submit regular reports to state legislative committees by December 1 of 2024, 2025, and 2026, detailing available drugs and explaining why certain approved options have not been included in standing orders. These changes aim to increase patient choice and improve transparency regarding the availability of life-saving overdose reversal treatments.